Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

505 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-08-21

Study Completion Date

2028-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combination of Sotyktu and Enstilar for Plaque Psoriasis

NCT06329258

Psoriasis

COMPLETED PHASE4

A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea

NCT02982005

Moderate to Severe Plaque Psoriasis

COMPLETED PHASE3

A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan

NCT05633264

Psoriasis

COMPLETED

A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

NCT06512337

Plaque Psoriasis

RECRUITING

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

NCT05701995

Psoriasis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Moderate-to-severe Plaque Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants diagnosed with moderate-to-severe plaque psoriasis

Deucravacitinib

Intervention Type DRUG

As per product label

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Deucravacitinib

As per product label

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult participants ≥19 years of age
* Diagnosis of moderate-to-severe plaque psoriasis
* Candidate for phototherapy or systemic therapy
* Will begin deucravacitinib according to approved product label

Exclusion Criteria

* Participants prescribed deucravacitinib for therapeutic indications not approved in Korea
* Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No